There are provided a compound of Formula (1) and a labeled biological substance having the compound.

##STR00001##

R.sup.1 to R.sup.6, R.sup.11 to R.sup.13, and R.sup.22 to R.sup.29 represent specific groups, and n is an integer of 1 to 3.

One selected from R.sup.1, R.sup.2, R.sup.5, R.sup.22 to R.sup.25 and one selected from R.sup.3, R.sup.4, R.sup.6, and R.sup.26 to R.sup.29 are bonded through a linking group LL.

The linking group LL represents a linking group having 1 to 100 atoms, which does not have any one of an aromatic hydrocarbon ring, a sulfo group, or a phosphono group.

R.sup.1, . . . , R.sup.6, R.sup.22, . . . , or R.sup.29 includes a structure represented by —(CH.sub.2—CH.sub.2—O).sub.m—, where m is 1 to 50.

The above-described compound is a neutral compound and contains at least one substituent capable of being bonded to a carboxy group or a biological substance.

An ICG fluorescence image measured with an excitation light of 740 nm and a fluorescence of 845 nm is shown in FIG. 10, and an ICG fluorescence image measured with an excitation light of 780 nm and a fluorescence of 845 nm is shown in FIG. 11, respectively. As a result, it was observed that the ICG derivative RGD2-PPA-Cy accumulated in the tumor tissue 30 minutes after tail vein administration, regardless of whether the wavelength of the excitation light was 740 nm or 780 nm.

Cyanine fluorophores including a nine-carbon polymethine bridge are disclosed. The cyanine fluorophores have absorbance and/or emission maxima in the near-infrared (NIR) and short-wave infrared (SWIR) wavelength ranges. Methods of making and using the cyanine fluorophores are also disclosed. The compounds are useful in fluorescence imaging, more particularly in cancer treatment. The compounds have generic formula (I): ##STR00001##

The invention provides a novel class of cyanine dyes that are functionalized with sulfonic acid groups and a linker moiety that facilitates their conjugation to other species and substituent groups which increase the water-solubility, and optimize the optical properties of the dyes. Also provided are conjugates of the dyes, methods of using the dyes and their conjugates and kits including the dyes and their conjugates.

The present invention relates to a compound of a pharmaceutically acceptable salt thereof of formula (I) wherein (A) is at least one motif specifically binding to cell membranes of neoplastic cells; (B) at least one chelator moiety of radiometals; (C) a dye moiety; x.sub.1 is a spacer or a chemical single bond covalently connecting (A) to the rest of the molecule; x.sub.2 is a spacer or a chemical single bond covalently connecting (C) to the rest of the molecule. The invention further relates to compositions comprising said compounds as well as a method for detecting neoplastic cells in a sample in vitro with the aid of the compounds or composition. ##STR00001##

Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.

A dye-drug conjugate for preventing, treating, or imaging cancer having the following structure:

##STR00001##

wherein R.sub.1 and R.sub.2 are independently selected from the group consisting of —H, alkyl, alkyl-sulphonate, alkylcarboxylic, alkylamino, aryl, —SO.sub.3H, —PO.sub.3H, —OH, —NH.sub.2, and -halogen; wherein Y.sub.1 and Y.sub.2 is independently selected from the group consisting of alkyl, aryl, aralkyl, alkylsulphonate, alkylcarboxylic, alkylamino, ω-alkylaminium, ω-alkynyl, PEGyl, PEGylcarboxylate, ω-PEGylaminium, ω-acyl-NH, ω-acyl-lysinyl-, ω-acyl-triazole, ω-PEGylcarboxyl-NH—, ω-PEGylcarboxyl-lysinyl, and ω-PEGylcarboxyl-triazole; wherein X is selected from the group consisting of a hydrogen, halogen, CN, Me, NH.sub.2, SH and OH; and R.sub.3 and R.sub.4 are independently a hydrogen, a therapeutic agent, or an imaging moiety, wherein the therapeutic agent is selected from the group consisting of a platinum-based therapeutic agent, a small molecule therapeutic agent, a peptide, a protein, a polymer, an siRNA, a microRNA, and a nanoparticle, wherein the imaging is a radio-isotope selected from the group consisting of F18, I-125, I-124 I-123, I-131, and small molecule labeled with any of these isotopes, or wherein the imaging moiety is a chelator-complexed radioactive isotope, wherein the radioactive isotope is selected from the group consisting of Cu-64, In-111, Tc-99m, Ga-68, Lu-177, Zo-89, Th-227 and Gd-157.

Near infrared and shortwave infrared dyes can have polymethine structures.

Disclosed herein are detectable moieties and detectable conjugates comprising one or more detectable moieties. In some embodiments, the disclosed detectable moieties have a narrow wavelength and are suitable for multiplexing. Also disclosed are methods of labeling one or more targets within a biological specimen using any of the detectable conjugates and/or detectable moieties described herein.

Provided is a coloring composition containing a coloring agent compound represented by Formula 1 and a medium.

##STR00001##

Description of T.sup.1, T.sup.2, R.sup.1, R.sup.2, X.sup.1, and n Formula 1 are omitted.